Hillevax
planned development and regulatory strategy focused on infant population followed by and or efficacy studies in older adults clinical program and recommendations establish efficacy in infants and bridge to older populations | Hillevax
Company
Deck Type
IPO
Sector
Industry
Deck date
April 2022
Slide
20 of 24
Related slides by other companies
DICE Therapeutics
Results
March 2023
key from phase efficacy results dice | DICE Therapeutics
AstraZeneca
Results
February 2023
oncology highlights novel programmes advance with new pivotal trials including in accelerated development in sensitive types longer follow up data for dose supports transition to late stage phase first patient dosed in five phase planned in across key types including current soc regimens new phase planned to initiate in expanded phase in development | AstraZeneca
Matinas BioPharma
Investor Presentation
March 2024
mat regulatory and development strategy | Matinas BioPharma
Matinas BioPharma
Investor Presentation
February 2024
mat regulatory and development strategy | Matinas BioPharma
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io